Business
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is supporting
About this update from Jaguar Health, Inc.
[{"type":"text","content":"New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the Japan Patent Office has issued a new Japan patent to Napo for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo's novel plant-based prescription drug.\"We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS,\" said Steven King Ph.D., Jaguar's Chief Sustainable Supply, Ethnobotanical Research and IP officer.Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease (MVID) with intestinal failure in the US, European Union, and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID, potentially in 2024, for these debilitating conditions.Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) from a few to up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the associated sequelae from diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, and other secondary symptoms, and these symptoms emerge either early or late, and many times become life-threatening.MVID, an ultrarare congenital diarrheal disorder (CDD), is a catastroph...